- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07259304
Social hälsa, aktivitetsbeteenden och livskvalitet bland unga vuxna cancersurvivorer
Social hälsa, aktivitetsbeteenden och livskvalitet bland unga vuxna cancersurvivorer: En longitudinell studie
This longitudinal observational study examines how social health, including social support, social roles, loneliness, social anxiety, and social network characteristics, relates to physical activity, sedentary time, and quality of life among ethnically and racially diverse adolescent and young adult (AYA) cancer patients aged 18-39 years. The study follows participants over four clinically significant timepoints in the first 12 months after diagnosis (baseline near diagnosis, mid treatment, near end of treatment, and 12 month follow up). At each timepoint, patients complete questionnaires and wear a wrist worn accelerometer for one week.
Studieöversikt
Status
Betingelser
- Malign fast neoplasma
- Hodgkins lymfom
- Bröstcancer i anatomisk stadium I AJCC v8
- Bröstcancer i anatomiskt stadium IA AJCC v8
- Anatomiskt stadium IB Bröstcancer AJCC v8
- Anatomisk steg II bröstcancer AJCC v8
- Anatomiskt stadium IIA Bröstcancer AJCC v8
- Anatomiskt stadium IIB Bröstcancer AJCC v8
- Anatomisk steg III bröstcancer AJCC v8
- Anatomisk steg IIIA Bröstcancer AJCC v8
- Anatomisk stadium IIIB bröstcancer AJCC v8
- Anatomisk stadium IIIC bröstcancer AJCC v8
- Prognostisk steg I bröstcancer AJCC v8
- Prognostisk stadium IA Bröstcancer AJCC v8
- Prognostisk stadium IB bröstcancer AJCC v8
- Prognostisk steg II bröstcancer AJCC v8
- Prognostisk stadium IIA bröstcancer AJCC v8
- Prognostisk stadium IIB bröstcancer AJCC v8
- Prognostisk steg III bröstcancer AJCC v8
- Prognostisk steg IIIA bröstcancer AJCC v8
- Prognostisk steg IIIB bröstcancer AJCC v8
- Prognostisk stadium IIIC bröstcancer AJCC v8
- Non-Hodgkin lymfom
- Stadium III Livmoderkroppscancer AJCC v8
- Kliniskt stadium III kutant melanom AJCC v8
- Patologiskt stadium IIIB kutant melanom AJCC v8
- Patologiskt stadium IIIC kutant melanom AJCC v8
- Patologiskt stadium IIID kutant melanom AJCC v8
- Kliniskt stadium I kutant melanom AJCC v8
- Kliniskt stadium IA kutant melanom AJCC v8
- Kliniskt stadium IB kutant melanom AJCC v8
- Kliniskt stadium II kutant melanom AJCC v8
- Kliniskt stadium IIA kutant melanom AJCC v8
- Kliniskt stadium IIB kutant melanom AJCC v8
- Kliniskt stadium IIC kutant melanom AJCC v8
- Patologiskt stadium I kutant melanom AJCC v8
- Patologiskt stadium IA kutant melanom AJCC v8
- Patologiskt stadium IB kutant melanom AJCC v8
- Patologiskt stadium II kutant melanom AJCC v8
- Patologiskt stadium IIA kutant melanom AJCC v8
- Patologiskt stadium IIB kutant melanom AJCC v8
- Patologiskt stadium IIC kutant melanom AJCC v8
- Patologiskt stadium III kutant melanom AJCC v8
- Patologiskt stadium IIIA kutant melanom AJCC v8
- Steg III kolorektal cancer AJCC v8
- Steg IIIA kolorektal cancer AJCC v8
- Steg IIIB kolorektal cancer AJCC v8
- Steg IIIC kolorektal cancer AJCC v8
- Steg I kolorektal cancer AJCC v8
- Steg II kolorektal cancer AJCC v8
- Steg IIA kolorektal cancer AJCC v8
- Steg IIB kolorektal cancer AJCC v8
- Steg IIC kolorektal cancer AJCC v8
- Steg I livmoderhalscancer AJCC v8
- Steg IA Livmoderhalscancer AJCC v8
- Steg IA1 Livmoderhalscancer AJCC v8
- Steg IA2 livmoderhalscancer AJCC v8
- Steg IB livmoderhalscancer AJCC v8
- Steg IB1 Livmoderhalscancer AJCC v8
- Steg IB2 livmoderhalscancer AJCC v8
- Steg II livmoderhalscancer AJCC v8
- Steg IIA Livmoderhalscancer AJCC v8
- Steg IIA1 Livmoderhalscancer AJCC v8
- Steg IIA2 Livmoderhalscancer AJCC v8
- Steg IIB livmoderhalscancer AJCC v8
- Steg III livmoderhalscancer AJCC v8
- Steg IIIA livmoderhalscancer AJCC v8
- Steg IIIB livmoderhalscancer AJCC v8
- Steg IIIA Livmoderkroppscancer AJCC v8
- Stadium IIIB Livmoderkroppscancer AJCC v8
- Stadium IIIC Livmoderkroppscancer AJCC v8
- Stadium IIIC1 Livmoderkroppscancer AJCC v8
- Stadium IIIC2 Livmoderkroppscancer AJCC v8
- Malign hjärnneoplasma
- Steg III äggstockscancer AJCC v8
- Steg IIIA äggstockscancer AJCC v8
- Steg IIIA1 äggstockscancer AJCC v8
- Steg IIIA2 äggstockscancer AJCC v8
- Steg IIIB äggstockscancer AJCC v8
- Steg IIIC äggstockscancer AJCC v8
- Neoplasma i centrala nervsystemet
- Steg III differentierad sköldkörtelkarcinom AJCC v8
- Steg III sköldkörtelmärgkarcinom AJCC v8
- Stadium I Livmoderkroppscancer AJCC v8
- Stadium IA Livmoderkroppscancer AJCC v8
- Stadium IB livmoderkroppscancer AJCC v8
- Steg II Livmoderkroppscancer AJCC v8
- Malign testikelneoplasm
- Steg II äggstockscancer AJCC v8
- Steg IIA äggstockscancer AJCC v8
- Steg IIB äggstockscancer AJCC v8
- Steg I äggstockscancer AJCC v8
- Steg IA äggstockscancer AJCC v8
- Steg IB äggstockscancer AJCC v8
- Steg IC äggstockscancer AJCC v8
- Malign benneoplasma
- Stadium I Differentierad Sköldkörtelcancer AJCC v8
- Stadium I medullärt sköldkörtelcarcinom AJCC v8
- Stadium II Differentierad Sköldkörtelcancer AJCC v8
- Stadium II medullärt sköldkörtelcarcinom AJCC v8
Intervention / Behandling
Detaljerad beskrivning
PRIMARY OBJECTIVES:
I. Characterize trajectories of social health over the course of cancer treatment and into early survivorship; II. Investigate longitudinal and potentially reciprocal associations between social health and activity behaviors (physical activity and sedentary time) and their relationship to quality of life; III. Examine whether gender, race/ethnicity, socioeconomic status, and symptom burden moderate these associations.
OUTLINE:
Patients complete surveys over 40 minutes and wear an actigraph GT3X-BT accelerometer continuously for 7 days at baseline, 3, 6, and 12 months.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
California
-
Los Angeles, California, Förenta staterna, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Förenta staterna, 90033
- Los Angeles General Medical Center
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- MD Anderson Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Patients diagnosed and/or treated with cancer between ages 18-39 at University of Southern California (USC) hospitals.
Beskrivning
Inclusion Criteria:
- Age 18-39 years at cancer diagnosis.
- Newly diagnosed (within past 3 months) with one of the following cancer types commonly seen in AYAs: testis, breast, thyroid, cervix, colorectal, brain/central nervous system, non Hodgkin lymphoma, uterine, melanoma, bones and joints, ovary, Hodgkin lymphoma, lung, or gastric cancer.
- Stage I-IV for solid tumors (AJCC 8th edition TNM staging) or I-IV for lymphomas (Ann Arbor staging).
- Receiving care at a participating USC affiliated hospital (USC Norris Comprehensive Cancer Center, Keck Hospital of USC, or Los Angeles General Medical Center) or MD Anderson Cancer Center.
- Clinician assessed expected survival greater than 12 months at time of diagnosis.
- Able to complete questionnaires and wear a wrist worn accelerometer.
- English or Spanish speaking.
Exclusion Criteria:
- Leukemia (excluded due to longer treatment duration and different care trajectory).
- Primary language other than English or Spanish.
- Cognitive or physical limitations that preclude completion of surveys or wearing an accelerometer.
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: CASE_ONLY
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Observational (actigraph, surveys)
Patients complete surveys and wear an actigraph GT3X-BT accelerometer continuously for 7 days at baseline, 3, 6, and 12 months. |
Wear an actigraph GT3X-BT accelerometer Complete survey
Andra namn:
Complete survey |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in social role functioning
Tidsram: Baseline up to 1 year
|
Assessed using the PROMIS Ability to Participate in Social Roles and Activities Short Form 4a, which measures limitations in participation in usual social roles and activities due to health (higher scores indicate better participation). |
Baseline up to 1 year
|
|
Change in perceived emotional support
Tidsram: Baseline up to 1 year
|
Assessed using the PROMIS Emotional Support Short Form 4a, which measures perceived availability of people who provide emotional support, such as care, understanding, and someone to listen (higher scores indicate more emotional support). |
Baseline up to 1 year
|
|
Change in perceived informational support
Tidsram: Baseline up to 1 year
|
Assessed using the PROMIS Informational Support Short Form 4a, which measures perceived availability of people who provide advice, information, and guidance (higher scores indicate more informational support). |
Baseline up to 1 year
|
|
Change in perceived instrumental support
Tidsram: Baseline up to 1 year
|
Assessed using the PROMIS Instrumental Support Short Form 4a, which measures perceived availability of people who provide practical help and assistance with tasks (higher scores indicate more instrumental support). |
Baseline up to 1 year
|
|
Change in loneliness score
Tidsram: Baseline up to 1 year
|
Assessed using the UCLA Loneliness Scale short form, which measures subjective feelings of loneliness and social disconnection (higher scores indicate greater loneliness). |
Baseline up to 1 year
|
|
Change in social anxiety symptoms
Tidsram: Baseline up to 1 year
|
Assessed using the Mini Social Phobia Inventory (Mini SPIN), a brief validated measure of social anxiety and fear of social interactions (higher scores indicate greater social anxiety). |
Baseline up to 1 year
|
|
Change in social network density
Tidsram: Baseline up to 1 year
|
Assessed using a study developed egocentric social network questionnaire in which participants list up to 10 important adult social contacts and indicate which contacts know each other; density is calculated as the proportion of possible ties that are present (higher values indicate a more densely connected network). |
Baseline up to 1 year
|
|
Change in proportion of supportive social ties
Tidsram: Baseline up to 1 year
|
Assessed using a study developed egocentric social network questionnaire that measures whether each named social contact provides social support and encouragement for physical activity; the outcome is the proportion of social ties providing support (higher values indicate a more supportive network). |
Baseline up to 1 year
|
|
Change in frequency of social contact
Tidsram: Baseline up to 1 year
|
Assessed using a study developed egocentric social network questionnaire that captures how often participants interact with each named social contact; the outcome is the average reported frequency of contact across alters (higher values indicate more frequent social contact). |
Baseline up to 1 year
|
|
Change in total daily physical activity
Tidsram: Baseline up to 1 year
|
Assessed using a wrist worn ActiGraph GT3X BT accelerometer worn for 7 consecutive days at each time point. Raw data are converted to monitor independent movement summary (MIMS) units, and total daily physical activity is represented by average daily MIMS units across valid wear days (higher values indicate more physical activity). |
Baseline up to 1 year
|
|
Change in total daily sedentary time
Tidsram: Baseline up to 1 year
|
Assessed using a wrist worn ActiGraph GT3X BT accelerometer worn for 7 consecutive days at each time point. Sedentary time is calculated from accelerometer data as average minutes per day spent in sedentary behavior (e.g., low movement periods while awake) across valid wear days (higher values indicate more sedentary time). |
Baseline up to 1 year
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Quality of Life
Tidsram: Baseline up to 1 year
|
Patient reported quality of life using Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health 10, assessed at baseline and 12 month follow up. This is a 10-item patient-reported questionnaire measuring general physical, mental, and social health. Most questions use a 1-to-5 point scale. Higher numerical values consistently represent better health or lower symptoms. The survey produces two separate scores: Global Physical Health (GPH) and Global Mental Health (GMH). Raw response values are summed and converted into standardized T-scores where a score of 50 represents the U.S. general population average (standard deviation of 10). |
Baseline up to 1 year
|
|
Symptom Burden
Tidsram: Baseline up to 1 year
|
Symptom burden assessed using the MD Anderson Symptom Inventory (MDASI) at all four timepoints. This survey is a multi-symptom patient-reported outcome (PRO) measure used to assess the severity of symptoms experienced by patients with cancer and the interference with daily living caused by these symptoms. |
Baseline up to 1 year
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Kimberly Miller, PhD, University of Southern California
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Sjukdomar i det endokrina systemet
- Skelettsjukdomar
- Muskuloskeletala sjukdomar
- Hjärnsjukdomar
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Genitala neoplasmer, manliga
- Urogenitala neoplasmer
- Neoplasmer efter plats
- Neoplasmer
- Genitala sjukdomar, manliga
- Manliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Tarmsjukdomar
- Immunsystemets sjukdomar
- Neoplasmer efter histologisk typ
- Gastrointestinala neoplasmer
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Gastrointestinala sjukdomar
- Intestinala neoplasmer
- Rektala sjukdomar
- Livmodersjukdomar
- Genitala sjukdomar, kvinnor
- Neoplasmer i endokrina körtel
- Neoplasmer, körtel och epitel
- Adenocarcinom
- Kolonsjukdomar
- Ovariella sjukdomar
- Adnexala sjukdomar
- Genitala neoplasmer, hona
- Gonadal sjukdomar
- Lymfatiska sjukdomar
- Lymfoproliferativa störningar
- Immunproliferativa störningar
- Carcinom
- Livmoderhalssjukdomar
- Neuroektodermala tumörer
- Neoplasmer, könsceller och embryonala
- Neoplasmer, nervvävnad
- Lymfom
- Neoplasmer i nervsystemet
- Uterina neoplasmer
- Neuroendokrina tumörer
- Neoplasmer, duktal, lobulär och medullär
- Karcinom, neuroendokrina
- Testikelsjukdomar
- Hemiska och lymfsjukdomar
- Kolorektala neoplasmer
- Ovariella neoplasmer
- Uterina cervikala neoplasmer
- Lymfom, icke-Hodgkin
- Hodgkins sjukdom
- Neoplasmer i hjärnan
- Neoplasmer i centrala nervsystemet
- Karcinom, medullär
- Testikulära neoplasmer
- Benneoplasmer
Andra studie-ID-nummer
- 0S-20-10
- P30CA014089 (U.S.S. NIH-anslag/kontrakt)
- 0S-20-10 (Annan identifierare: USC / Norris Comprehensive Cancer Center)
- NCI-2021-05723 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- R37CA256867 (U.S.S. NIH-anslag/kontrakt)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .